Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.

Autor: O'Malley DM; Division of Gynecologic Oncology, The Ohio State University/James Comprehensive Cancer Center, Columbus, OH., Neffa M; CI of Healthcare Regional Clinical Specialized Dispensary of the Radiation Protection, Kharvik, Ukraine., Monk BJ; Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona, Creighton University, Phoenix, AZ., Melkadze T; Research Institute of Clinical Medicine, Tbilisi, Georgia., Huang M; Division of Gynecologic Oncology, University of Miami School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL., Kryzhanivska A; Regional Clinical Oncology Center, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine., Bulat I; ARENSIA Exploratory Medicine Unit, Institute of Oncology, Chisinau, Moldova., Meniawy TM; Linear Clinical Research, Nedlands, Australia., Bagameri A; Országos Onkológiai Intézet, Budapest, Hungary., Wang EW; Medical Oncology and Therapeutic Research, City of Hope Comprehensive Cancer Center, Duarte, CA., Doger de Speville Uribe B; START Madrid FJD, Madrid, Spain., Hegg R; Clínica de Pesquisa e Centro de Estudos em Oncologia Ginecológica e Mamária, Sao Paulo, Brazil., Ortuzar Feliu W; Agenus Inc, Waltham, MA., Ancukiewicz M; Agenus Inc, Waltham, MA., Lugowska I; Maria Sklodowska-Curie National Research Unit of Oncology, Warsaw, Poland.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2022 Mar 01; Vol. 40 (7), pp. 762-771. Date of Electronic Publication: 2021 Dec 21.